25 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
pricing limitations may, therefore, hinder our ability to recoup our investment in one or more of our product candidates, even if our product candidates
ARS
rs2ysgepgmnmug02 ydi
28 Apr 23
Annual report to shareholders
7:03am
424B4
2krf1r vh
21 Jun 21
Prospectus supplement with pricing info
8:08am
DRS
yh7y6
19 May 21
Draft registration statement
12:00am
10-K
zg18f7
11 Mar 21
Annual report
4:19pm